{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:07:45Z","timestamp":1774523265751,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s10549-012-2072-y","type":"journal-article","created":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T10:29:31Z","timestamp":1335781771000},"page":"683-692","source":"Crossref","is-referenced-by-count":65,"title":["Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study"],"prefix":"10.1007","volume":"134","author":[{"given":"Lawrence J.","family":"Solin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori J.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abram","family":"Recht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick L.","family":"Baehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Shak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Badve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence N.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"George W.","family":"Sledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"2072_CR1","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","volume":"28","author":"EP Mamounas","year":"2010","unstructured":"Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677\u20131683","journal-title":"J Clin Oncol"},{"key":"2072_CR2","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1158\/1078-0432.CCR-08-2644","volume":"15","author":"B Kreike","year":"2009","unstructured":"Kreike B, Halfwerk H, Armstrong N et al (2009) Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 15:4181\u20134190","journal-title":"Clin Cancer Res"},{"key":"2072_CR3","doi-asserted-by":"publisher","first-page":"R62","DOI":"10.1186\/bcr1614","volume":"8","author":"DS Nuyten","year":"2006","unstructured":"Nuyten DS, Kreike B, Hart AA et al (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62","journal-title":"Breast Cancer Res"},{"key":"2072_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc KD, Cheang M, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684\u20131691","journal-title":"J Clin Oncol"},{"key":"2072_CR5","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1200\/JCO.2008.21.7075","volume":"27","author":"EK Millar","year":"2009","unstructured":"Millar EK, Graham PH, O\u2019Toole SA et al (2009) Prediction of local recurrence, distant metastasis, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701\u20134708","journal-title":"J Clin Oncol"},{"key":"2072_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3816\/CBC.2009.n.018","volume":"9","author":"LJ Solin","year":"2009","unstructured":"Solin LJ, Hwang W-T, Vapiwala N (2009) Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer 9:96\u2013100","journal-title":"Clin Breast Cancer"},{"key":"2072_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/cncr.24094","volume":"115","author":"GM Freedman","year":"2009","unstructured":"Freedman GM, Anderson PR, Li T et al (2009) Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946\u2013951","journal-title":"Cancer"},{"key":"2072_CR8","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"BG Haffty","year":"2006","unstructured":"Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652\u20135657","journal-title":"J Clin Oncol"},{"key":"2072_CR9","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429\u20134434","journal-title":"Clin Cancer Res"},{"key":"2072_CR10","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","volume":"26","author":"PL Nguyen","year":"2008","unstructured":"Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373\u20132378","journal-title":"J Clin Oncol"},{"key":"2072_CR11","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329\u20132334","journal-title":"Clin Cancer Res"},{"key":"2072_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","volume":"8","author":"S Cleator","year":"2007","unstructured":"Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235\u2013244","journal-title":"Lancet Oncol"},{"key":"2072_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.22381","volume":"109","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25\u201332","journal-title":"Cancer"},{"key":"2072_CR14","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","volume":"26","author":"EA Rakha","year":"2008","unstructured":"Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568\u20132581","journal-title":"J Clin Oncol"},{"key":"2072_CR15","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.2010.32.1877","volume":"29","author":"LF Hernandez-Aya","year":"2011","unstructured":"Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628\u20132634","journal-title":"J Clin Oncol"},{"key":"2072_CR16","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1200\/JCO.2010.33.4714","volume":"29","author":"BS Abdulkarim","year":"2011","unstructured":"Abdulkarim BS, Cuartero J, Hanson J et al (2011) Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29:2852\u20132857","journal-title":"J Clin Oncol"},{"key":"2072_CR17","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1200\/JCO.2008.16.7841","volume":"26","author":"LJ Goldstein","year":"2008","unstructured":"Goldstein LJ, O\u2019Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E2197. J Clin Oncol 26:4092\u20134099","journal-title":"J Clin Oncol"},{"key":"2072_CR18","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1200\/JCO.2007.14.4501","volume":"26","author":"LJ Goldstein","year":"2008","unstructured":"Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063\u20134071","journal-title":"J Clin Oncol"},{"key":"2072_CR19","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1158\/1078-0432.CCR-09-1450","volume":"15","author":"JA Sparano","year":"2009","unstructured":"Sparano JA, Goldstein LJ, Childs BH et al (2009) Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 15:7693\u20137700","journal-title":"Clin Cancer Res"},{"key":"2072_CR20","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1200\/JCO.2007.13.6424","volume":"26","author":"SS Badve","year":"2008","unstructured":"Badve SS, Baehner FL, Gray RP et al (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473\u20132481","journal-title":"J Clin Oncol"},{"key":"2072_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10985-008-9095-z","volume":"15","author":"RJ Gray","year":"2009","unstructured":"Gray RJ (2009) Weighted analysis for cohort sampling designs. Lifetime Data Anal 15:24\u201340","journal-title":"Lifetime Data Anal"},{"key":"2072_CR22","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1002\/sim.3402","volume":"27","author":"PK Ruan","year":"2008","unstructured":"Ruan PK, Gray RJ (2008) Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 27:5709\u20135724","journal-title":"Stat Med"},{"key":"2072_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1075-122X.2006.00297.x","volume":"12","author":"EE Harris","year":"2006","unstructured":"Harris EE, Hwang W-T, Lee EA et al (2006) The impact of HER-2 status on local recurrence in women with stage I\u2013II breast cancer treated with breast-conserving therapy. Breast J 12:431\u2013436","journal-title":"Breast J"},{"key":"2072_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55\u201365","journal-title":"Lancet Oncol"},{"key":"2072_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-010-1331-z","volume":"127","author":"G Tang","year":"2011","unstructured":"Tang G, Shak S, Paik S et al (2011) Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP-B-14 and NSABP B-20. Breast Cancer Res Treat 127:133\u2013142","journal-title":"Breast Cancer Res Treat"},{"key":"2072_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/cncr.21121","volume":"104","author":"N Cabioglu","year":"2005","unstructured":"Cabioglu N, Hunt KK, Buchholz TA et al (2005) Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104:20\u201329","journal-title":"Cancer"},{"key":"2072_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/cncr.20410","volume":"101","author":"H Pass","year":"2004","unstructured":"Pass H, Vicini FA, Kestin LL et al (2004) Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution. Cancer 101:713\u2013720","journal-title":"Cancer"},{"key":"2072_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"2072_CR29","unstructured":"Halyard MY, Dueck AC, Pisansky TM et al (2010) Impact of adjuvant trastuzumab on local regional recurrence: Data from the North Central Cancer Treatment Group (NCCTG) N9831 study (Abstract). Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, 8\u201312 December 2010"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2072-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2072-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2072-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2072-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T19:31:00Z","timestamp":1581967860000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2072-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["2072"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2072-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,1]]}}}